Company recalls application for hormone-refractory PCa drug
GPC Biotech AG has retracted its new drug application for satraplatin, which was submitted for rapid approval to treat hormone-refractory prostate cancer patients who had experienced unsuccessful previous chemotherapy.
GPC Biotech AG has retracted its new drug application for satraplatin, which was submitted for rapid approval to treat hormone-refractory prostate cancer patients who had experienced unsuccessful previous chemotherapy.
The withdrawal was the result of a vote on July 24, 2007, by the Oncologic Drugs Advisory Committee to FDA that stated FDA should hold off on approval until the final survival analysis of a satraplatin trial known as SPARC was completed. SPARC trial results are expected within 5 months.
If the overall survival data from the SPARC trial are positive, GPC Biotech said it would submit a new drug application to the FDA "as quickly as possible."
Malpractice Consult: How likely are you to face a medical malpractice lawsuit?
July 23rd 2024"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
UK study of AI-based software for prostate cancer detection expands
July 22nd 2024"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and patients, and looking at the impact on workflow," says Clare Verrill, BM, FRCPath, MMedEd.
